

1639

DOCKET NO.: M0656.70071US00

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Vernon M. Ingram et al.  
Serial No: 10/051,663  
Confirmation. No.: 3098  
Filed: January 18, 2002  
For: TREATMENT FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE

Examiner: Celsa, Bennett M.  
Art Unit: 1639

---

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 15th day of January, 2004.

  
June Watson

---

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- ☒ **Response to Communication**
- ☒ **Information Disclosure Statement**
- ☒ **PTO-1449 Form with cited references**
- ☒ **Return Receipt Postcard**

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No fee is enclosed. If a fee is necessary, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,  
Vernon M. Ingram et al., Applicant

  
John R. Van Amsterdam, Reg. No.: 40,212  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2211  
Telephone: (617)720-3500

Docket No. M0656.70071US00

Date: January 15, 2004  
x01/15/04

762287.1



DOCKET NO: M0656.70071US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Vernon M. Ingram et al.  
Serial No: 10/051,663  
Confirmation No: 3098  
Filed: January 18, 2002  
For: TREATMENT FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE

Examiner: Celsa, Bennett M.  
Art Unit: 1639

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 15<sup>th</sup> day of January, 2004.

  
June Watson

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO COMMUNICATION**

Sir:

This is responsive to the Office Communication mailed on December 15, 2003 requiring an election of a compound that decreases neuronal membrane depolarization and a compound that decreases neuronal calcium influx.

Pursuant to the Examiner's requirement for the election of a single disclosed species for a compound that decreases neuronal membrane depolarization and a single disclosed species for a compound that decreases neuronal calcium influx, Applicant elects the following compounds.

For a compound that decreases neuronal membrane depolarization, Applicants elect (as in the response to the restriction requirement) tyrosine kinase inhibitor DAPH1 (4,5-dianilinophthalimide). The chemical structure of DAPH1 is shown below: